Pharmaceutical major Lupin Ltd on Monday said it has received approval from the US Food and Drugs Administration (FDA) to market a generic version of GD Searle LLC's Celebrex capsules, used to treat arthritis, in the American market.

The Mumbai-based company has received final approval for its Celecoxib Capsules in 50 mg strength from the US health regulator (FDA) to market a generic version of GD Searle LLC's Celebrex capsules, Lupin said in a statement.

The company has also received tentative approvals for its product in strengths of 100 mg, 200 mg and 400 mg from the FDA, it added.